Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magdalena Zamora

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Endocrinology|May 14, 2024
Immunometric and functional measurement of endogenous vasoinhibin in human seraMagdalena Zamora, David Harris, Nils Davies, et al.
Endocrinology|August 21, 2021
Thrombin Cleaves Prolactin Into a Potent 5.6-kDa Vasoinhibin: Implication for Tissue RepairMagdalena Zamora, Juan Pablo Robles, Manuel B Aguilar, et al.
Scientific Reports|November 22, 2018
Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residuesJuan Pablo Robles, Magdalena Zamora, José Luis Velasco-Bolom, et al.
Endocrinology|February 4, 2025
Vasoinhibin is Generated by the Renin-angiotensin SystemFrancisco Freinet Núñez, Lourdes Siqueiros-Marquez, Elva Adán-Castro, et al.
Scientific Reports|July 23, 2025
Topical ophthalmic administration of the antiangiogenic peptide VIAN-c4551 protects against experimental diabetic macular edemaElva Adán-Castro, Magdalena Zamora, Daniela Granados-Carrasco, et al.
Angiogenesis|June 7, 2021
The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptideJuan Pablo Robles, Magdalena Zamora, Lourdes Siqueiros-Marquez, et al.
Drug Development Research|October 7, 2025
Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From VasoinhibinMiguel A García-González, Alejandro D Miguel-Martínez, Abimael González-Hernández, et al.
Translational Vision Science & Technology|September 4, 2020
Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic RetinopathyCarlos D Nuñez-Amaro, Aura Ileana Moreno-Vega, Elva Adan-Castro, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Endocrinology|May 14, 2024
Immunometric and functional measurement of endogenous vasoinhibin in human seraMagdalena Zamora, David Harris, Nils Davies, et al.
Endocrinology|August 21, 2021
Thrombin Cleaves Prolactin Into a Potent 5.6-kDa Vasoinhibin: Implication for Tissue RepairMagdalena Zamora, Juan Pablo Robles, Manuel B Aguilar, et al.
Scientific Reports|November 22, 2018
Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residuesJuan Pablo Robles, Magdalena Zamora, José Luis Velasco-Bolom, et al.
Endocrinology|February 4, 2025
Vasoinhibin is Generated by the Renin-angiotensin SystemFrancisco Freinet Núñez, Lourdes Siqueiros-Marquez, Elva Adán-Castro, et al.
Scientific Reports|July 23, 2025
Topical ophthalmic administration of the antiangiogenic peptide VIAN-c4551 protects against experimental diabetic macular edemaElva Adán-Castro, Magdalena Zamora, Daniela Granados-Carrasco, et al.
Angiogenesis|June 7, 2021
The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptideJuan Pablo Robles, Magdalena Zamora, Lourdes Siqueiros-Marquez, et al.
Drug Development Research|October 7, 2025
Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From VasoinhibinMiguel A García-González, Alejandro D Miguel-Martínez, Abimael González-Hernández, et al.
Translational Vision Science & Technology|September 4, 2020
Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic RetinopathyCarlos D Nuñez-Amaro, Aura Ileana Moreno-Vega, Elva Adan-Castro, et al.
Pageof 2